Get started
Author

Brigitte A. Barrette

Observed names: B A Barrette, B. A. Barrette, B. Barrette, Brigitte Barrette
OpenAlex ID: A5081575757
Phase I Trial of Intraperitoneal Administration of an Oncolytic Measles Virus Strain Engineered to Express Carcinoembryonic Antigen for Recurrent Ovarian Cancer
2010 · Evanthia Galanis, Lynn C. Hartmann, et al. · Cancer Research · 317
PDF
Lymphedema After Surgery for Endometrial Cancer
2014 · Kathleen J. Yost, Andrea L. Cheville, et al. · Obstetrics and Gynecology · 232
EGF/ErbB Receptor Family in Ovarian Cancer
2002 · N. J. Maihle, A. T. Baron, et al. · Springer eBooks · 116
Gynecologic Cancers: Factors Affecting Survival After Pulmonary Metastasectomy
2006 · Jose M. Clavero, Claude Deschamps, et al. · The Annals of Thoracic Surgery · 78
Gynecologic Cancer InterGroup (GCIG) Consensus Review
2014 · Martee L. Hensley, Brigitte A. Barrette, et al. · International Journal of Gynecological Cancer · 69
Gynecologic Cancer InterGroup (GCIG) Consensus Review for Carcinoid Tumors of the Ovary
2014 · Nicholas Simon Reed, Eva Gomez-Garcia, et al. · International Journal of Gynecological Cancer · 66
Ovarian Cancer: The Neglected Diagnosis
2004 · Barbara P. Yawn, Brigitte A. Barrette, et al. · Mayo Clinic Proceedings · 47
A Mixed-Methods Feasibility Trial of Protein Kinase C Iota Inhibition with Auranofin in Asymptomatic Ovarian Cancer Patients
2014 · Aminah Jatoi, Carmen Radecki Breitkopf, et al. · Oncology · 36
Overexpression of p34 cdc2 Protein Kinase in Epithelial Ovarian Carcinoma
1997 · Brigitte A. Barrette, Preeti J. Srivatsa, et al. · Mayo Clinic Proceedings · 14
Phase I trial of autologous hematopoietic SCT with escalating doses of topotecan combined with CY and carboplatin in patients with relapsed or persistent ovarian or primary peritoneal carcinoma
2009 · M R Litzow, P P Peethambaram, et al. · Bone Marrow Transplantation · 10
Self-reported verbal abuse in 1300+ older women within a private, tertiary women’s health clinic
2016 · Richa Sood, Paul Novotny, et al. · Archives of Gerontology and Geriatrics · 4
Outcomes in women age 40 years and older with cytologically benign endometrial cells
2012 · Petra M. Casey, Mary M. Gallenberg, et al. · American Journal of Obstetrics and Gynecology · 1
Supplementary Figure 3 from Phase I Trial of Intraperitoneal Administration of an Oncolytic Measles Virus Strain Engineered to Express Carcinoembryonic Antigen for Recurrent Ovarian Cancer
2023 · Evanthia Galanis, Lynn C. Hartmann, et al.
PDF
Supplementary Figure 5 from Phase I Trial of Intraperitoneal Administration of an Oncolytic Measles Virus Strain Engineered to Express Carcinoembryonic Antigen for Recurrent Ovarian Cancer
2023 · Evanthia Galanis, Lynn C. Hartmann, et al.
PDF
Supplementary Figure 2 from Phase I Trial of Intraperitoneal Administration of an Oncolytic Measles Virus Strain Engineered to Express Carcinoembryonic Antigen for Recurrent Ovarian Cancer
2023 · Evanthia Galanis, Lynn C. Hartmann, et al.
Supplementary Table 1 from Phase I Trial of Intraperitoneal Administration of an Oncolytic Measles Virus Strain Engineered to Express Carcinoembryonic Antigen for Recurrent Ovarian Cancer
2023 · Evanthia Galanis, Lynn C. Hartmann, et al.
PDF
Supplementary Figure 5 from Phase I Trial of Intraperitoneal Administration of an Oncolytic Measles Virus Strain Engineered to Express Carcinoembryonic Antigen for Recurrent Ovarian Cancer
2023 · Evanthia Galanis, Lynn C. Hartmann, et al.
Supplementary Figure Legends 1-5 from Phase I Trial of Intraperitoneal Administration of an Oncolytic Measles Virus Strain Engineered to Express Carcinoembryonic Antigen for Recurrent Ovarian Cancer
2023 · Evanthia Galanis, Lynn C. Hartmann, et al.
Supplementary Table 1 from Phase I Trial of Intraperitoneal Administration of an Oncolytic Measles Virus Strain Engineered to Express Carcinoembryonic Antigen for Recurrent Ovarian Cancer
2023 · Evanthia Galanis, Lynn C. Hartmann, et al.
Supplementary Figure 4 from Phase I Trial of Intraperitoneal Administration of an Oncolytic Measles Virus Strain Engineered to Express Carcinoembryonic Antigen for Recurrent Ovarian Cancer
2023 · Evanthia Galanis, Lynn C. Hartmann, et al.
Supplementary Figure 3 from Phase I Trial of Intraperitoneal Administration of an Oncolytic Measles Virus Strain Engineered to Express Carcinoembryonic Antigen for Recurrent Ovarian Cancer
2023 · Evanthia Galanis, Lynn C. Hartmann, et al.
Supplementary Figure 2 from Phase I Trial of Intraperitoneal Administration of an Oncolytic Measles Virus Strain Engineered to Express Carcinoembryonic Antigen for Recurrent Ovarian Cancer
2023 · Evanthia Galanis, Lynn C. Hartmann, et al.
PDF
Supplementary Figure 1 from Phase I Trial of Intraperitoneal Administration of an Oncolytic Measles Virus Strain Engineered to Express Carcinoembryonic Antigen for Recurrent Ovarian Cancer
2023 · Evanthia Galanis, Lynn C. Hartmann, et al.
Supplementary Figure 4 from Phase I Trial of Intraperitoneal Administration of an Oncolytic Measles Virus Strain Engineered to Express Carcinoembryonic Antigen for Recurrent Ovarian Cancer
2023 · Evanthia Galanis, Lynn C. Hartmann, et al.
PDF
Supplementary Figure 1 from Phase I Trial of Intraperitoneal Administration of an Oncolytic Measles Virus Strain Engineered to Express Carcinoembryonic Antigen for Recurrent Ovarian Cancer
2023 · Evanthia Galanis, Lynn C. Hartmann, et al.
PDF
Works count: 30
Citation count: 990
H-index: 10
I10-index: 10
Year
Topic
Type